TABLE I.
Demographics of Endometrial Cancer
| LVSI-positive |
LVSI-negative |
||
|---|---|---|---|
| No. | n=70 | n=641 | P-value |
| Age | 57.8 (± 9.4) | 52.8 (± 11.0) | <0.001 |
| <60 | 38 (54.3%) | 475 (74.1%) | |
| ≥60 | 32 (45.7%) | 166 (25.9%) | |
| Ethnicity | 0.005 | ||
| Caucasian | 14 (20.0%) | 118 (18.4%) | |
| African American | 0 | 26 (4.1%) | |
| Hispanic | 38 (54.3%) | 419 (65.4%) | |
| Asian | 18 (25.7%) | 78 (12.2%) | |
| BMI (kg/m2) | 31.7 (± 7.9) | 36.3 (± 10.1) | <0.001 |
| <30 | 33 (47.1%) | 179 (28.2%) | |
| ≥30 | 37 (52.9%) | 456 (71.8%) | |
| Histology | 0.001 | ||
| Endometrioid | 53 (75.7%) | 582 (909.8%) | |
| Serous | 8 (11.4%) | 33 (5.1%) | |
| Clear | 5 (7.1%) | 13 (2.0%) | |
| Others | 4 (5.7%) | 13 (2.0%) | |
| Grade | <0.001 | ||
| 1 | 11 (15.7%) | 428 (66.8%) | |
| 2 | 22 (31.4%) | 138 (21.5%) | |
| 3 | 37 (42.9%) | 75 (11.7%) | |
| Stage | <0.001 | ||
| I | 35 (50.0%) | 551 (86.0%) | |
| II | 4 (5.7%) | 47 (7.3%) | |
| III | 31 (44.3%) | 43 (6.7%) | |
| Myometrial invasion (%) | 70 (1–100) | 13 (0–100) | <0.001 |
| ≤50% | 25 (35.7%) | 554 (87.5%) | |
| >50% | 45 (64.3%) | 79 (12.5%) | |
| Cervical stromal invasion | <0.001 | ||
| No | 54 (77.1%) | 598 (93.4%) | |
| Yes | 16 (22.9%) | 42 (6.6%) | |
| Adnexal involvement | <0.001 | ||
| No | 58 (82.9%) | 615 (93.6%) | |
| Yes | 12 (17.1%) | 42 (6.4%) | |
| Pelvic node metastasis | <0.001 | ||
| No | 33 (60.0%) | 236 (97.1%) | |
| Yes | 22 (40.0%) | 7 (2.9%) | |
| Para-aortic node metastasis | 0.007 | ||
| No | 18 (69.2%) | 62 (92.5%) | |
| Yes | 8 (30.8%) | 5 (7.5%) | |
| Radiotherapy type | <0.001 | ||
| None | 12 (17.1%) | 486 (76.2%) | |
| ICBT alone | 24 (34.3%) | 77 (12.1%) | |
| WPRT alone | 21 (30.0%) | 41 (6.4%) | |
| WPRT + ext | 4 (5.7%) | 1 (0.2%) | |
| WPRT + ICBT | 9 (12.9%) | 31 (4.9%) | |
| WPRT + ext + ICBT | 0 | 2 (0.3%) | |
| Chemotherapy type* | <0.001 | ||
| None | 28 (40.0%) | 554 (86.6%) | |
| Carboplatin + paclitaxel | 37 (52.9%) | 77 (12.0%) | |
| Other | 5 (7.1%) | 9 (1.4%) |
Number (%), mean (± SD), or median (range) are shown. Student t test, Mann–Whitney U test, chi-square test, or Fisher exact test for P-values. Significant P-values are in bold.
*
median 6 cycles (range 3–10) for chemotherapy recipients. 6 missing for BMI, 8 missing for myometrial tumor invasion, 2 missing for cervical stromal invasion, 1 missing for adnexal involvement. 3 missing for radiotherapy, 3 missing for chemotherapy. Pelvic and para-aortic lymphadenectomy were performed in 308 and 99 cases, respectively.
BMI, body mass index; LVSI, lymphovascular space invasion; ICBT, intracavitary brachytherapy; WPRT, whole pelvis radiotherapy; and ext, extended filed to cover aortic nodal chain.